1015 / 1578
/
Ø
RCHT well tolerated
Ø
No improvement of OS, median 15 – 16.5 mo
Ø
Boarderline improvement of PFS
Pancreatic cancer – LAP 007
Hammel YAMA 2016
Overall survival
PF survival
ESTRO SBRT 2017 - Matthias Guckenberger
7
/
Published illustration
of pancreatic SBRT:
No (obvious) safety margin:
• Imaging for extension of diease?
• Microscopic disease?
• Residual uncertainties?
Despite small (zero) safety margin:
• Full dose to adjacant duodenal
wall
• Relevant doses to intestine
Pancreatic cancer
ESTRO SBRT 2017 - Matthias Guckenberger
8